Portfolio Company · Medical Devices
Ehmet Health
Precision Radiotherapy. Redefined.
Current portfolio2015Founded
PlymouthMichigan HQ
FDARegistered facility
About the company
Ehmet Health
Ehmet Health is a medical device company in Plymouth, Michigan that develops radiation therapy systems for cancer centers and clinics. Its two platforms are MAMMOKNIFE, a self shielded, prone position linear accelerator built only for breast cancer radiotherapy, and KODA ONE, a scalable synchrotron based proton therapy system. The company's stated goal is to simplify operations for providers and widen patient access to advanced radiotherapy, including in settings where building a traditional shielded vault is impractical.
What they do
Products and services
01MAMMOKNIFEA self shielded, image guided rotational LINAC dedicated to breast radiotherapy, with the patient treated face down to spare the heart and lungs
02KODA ONEA pencil beam scanning proton therapy system configurable from one to four treatment rooms
03Unified software platform linking imaging, treatment planning, delivery and system controls
04X ray 3D CBCT patient positioning software for proton therapy, FDA 510(k) cleared in 2018 and used at the McLaren Proton Therapy Center
05Custom radiotherapy configurations designed with each clinic
Leadership
Meet the team
Co-founder and CEOMichael TeicherHealthcare executive with capital markets and medical device experience who previously led a turnaround as CEO of a point of care CT company.LinkedIn →
CTONeal ClinthorneResearch Professor Emeritus in Radiology at the University of Michigan.LinkedIn →
CFOKevin MurphyFormer Wall Street executive with MBAs from MIT and Columbia.
VP, Quality and Regulatory AffairsDaniel Schoettlin
VP, Software EngineeringMilos Vujasevic
VP, Marketing, Communications and Business AffairsEmily PhillipsLinkedIn →
Milestones
Along the way
- September 2017As EhmetDx, signed an agreement with Orbital Therapy of Waltham, MA for exclusive rights to the MammoKnife self shielded breast radiotherapy device
- December 2018Received FDA 510(k) clearance for X ray 3D CBCT positioning software used at the McLaren proton therapy center
- August 2020Expanded management team with a Chief Medical Officer and Chief Financial Officer to prepare for commercialization
- February 2024Partner McLaren Proton Therapy Center treated its 1,000th patient
- November 2025Leadership visit to strengthen partnership with Jiaxing Proton Oncology Center in China
- May 2026Officially unveiled MAMMOKNIFE at ESTRO 2026 in Stockholm; its symposium drew more than 160 attendees
In the news
Press
PR Newswire · September 2017EhmetDx inks deal for the world's first self shielded radiotherapy deviceRead →NS Medical Devices · December 2018EhmetDx gets FDA nod for X-Ray 3D CBCT positioning softwareRead →Ehmet Health press release · August 2020Ehmet Health management team expands with veteran CMO and CFO to prepare for full commercializationRead →Ehmet Health News · May 2026From Concept to Congress: MAMMOKNIFE ESTRO 2026 LaunchRead →
Chart Organization
More from the portfolio
Company information from ehmethealth.com and public sources.